000274026 001__ 274026
000274026 005__ 20250119000231.0
000274026 0247_ $$2doi$$a10.1186/s13195-024-01647-w
000274026 0247_ $$2pmid$$apmid:39736793
000274026 0247_ $$2pmc$$apmc:PMC11687143
000274026 0247_ $$2altmetric$$aaltmetric:172560122
000274026 037__ $$aDZNE-2025-00007
000274026 041__ $$aEnglish
000274026 082__ $$a610
000274026 1001_ $$aMohaupt, Pablo$$b0
000274026 245__ $$aBlood-based biomarkers and plasma Aβ assays in the differential diagnosis of Alzheimer's disease and behavioral-variant frontotemporal dementia.
000274026 260__ $$aLondon$$bBioMed Central$$c2024
000274026 3367_ $$2DRIVER$$aarticle
000274026 3367_ $$2DataCite$$aOutput Types/Journal article
000274026 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1736336517_683
000274026 3367_ $$2BibTeX$$aARTICLE
000274026 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000274026 3367_ $$00$$2EndNote$$aJournal Article
000274026 520__ $$aThe differentiation between Alzheimer's disease (AD) and behavioral-variant frontotemporal dementia (bvFTD) can be complicated in the initial phase by shared symptoms and pathophysiological traits. Nevertheless, advancements in understanding AD's diverse pathobiology suggest the potential for establishing blood-based methods for differential diagnosis.We devised a novel assay combining immunoprecipitation and mass spectrometry (IP-MS) to quantify Amyloid-beta (Aβ) peptides in plasma. We then assessed its performance against existing assays (Shimadzu and Simoa) and evaluated a range of other blood-based biomarkers, including GFAP, NfL, and pTau-181, for differentiating between AD and bvFTD.The novel IP-MS assay measuring the Aβ42/40 ratio demonstrated an AUC of 0.82 for differentiating AD from control subjects. While it did not significantly outperform the composite biomarker score from the Shimadzu assay (AUC = 0.79, P = 0.67), it significantly outperformed the Shimadzu Aβ42/40 ratio (AUC = 0.65, P = 0.037) and the Simoa Aβ42/40 assay (AUC = 0.57, P = 0.023). Aβ biomarkers provided limited utility in distinguishing AD from bvFTD. In contrast, pTau181 and GFAP exhibited strong discriminatory power for differentiating AD from bvFTD, with AUCs of 0.90 and 0.87, respectively. Combining pTau181 and GFAP enhanced diagnostic accuracy, achieving an AUC of 0.94.We introduced a novel IP-MS assay that demonstrated comparable precision to the Shimadzu composite score in differentiating AD from non-neurodegenerative control groups. However, Aβ levels did not enhance the discrimination between AD and bvFTD. Furthermore, our findings support the utility of combining pTau181 and GFAP as a robust strategy for the blood-based differentiation of AD and bvFTD.
000274026 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000274026 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000274026 650_7 $$2Other$$aAlzheimer’s disease
000274026 650_7 $$2Other$$aAmyloid-beta
000274026 650_7 $$2Other$$aBlood biomarker
000274026 650_7 $$2Other$$aDementia
000274026 650_7 $$2Other$$aDifferential diagnosis
000274026 650_7 $$2Other$$aFrontotemporal lobar degeneration
000274026 650_7 $$2Other$$aMass spectrometry
000274026 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000274026 650_7 $$2NLM Chemicals$$aBiomarkers
000274026 650_7 $$2NLM Chemicals$$atau Proteins
000274026 650_7 $$2NLM Chemicals$$aPeptide Fragments
000274026 650_7 $$2NLM Chemicals$$aGlial Fibrillary Acidic Protein
000274026 650_7 $$2NLM Chemicals$$aamyloid beta-protein (1-42)
000274026 650_7 $$2NLM Chemicals$$aGFAP protein, human
000274026 650_7 $$2NLM Chemicals$$aneurofilament protein L
000274026 650_7 $$2NLM Chemicals$$aNeurofilament Proteins
000274026 650_7 $$2NLM Chemicals$$aamyloid beta-protein (1-40)
000274026 650_2 $$2MeSH$$aHumans
000274026 650_2 $$2MeSH$$aAlzheimer Disease: blood
000274026 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000274026 650_2 $$2MeSH$$aAmyloid beta-Peptides: blood
000274026 650_2 $$2MeSH$$aFrontotemporal Dementia: blood
000274026 650_2 $$2MeSH$$aFrontotemporal Dementia: diagnosis
000274026 650_2 $$2MeSH$$aDiagnosis, Differential
000274026 650_2 $$2MeSH$$aBiomarkers: blood
000274026 650_2 $$2MeSH$$aFemale
000274026 650_2 $$2MeSH$$aAged
000274026 650_2 $$2MeSH$$aMale
000274026 650_2 $$2MeSH$$atau Proteins: blood
000274026 650_2 $$2MeSH$$atau Proteins: cerebrospinal fluid
000274026 650_2 $$2MeSH$$aMiddle Aged
000274026 650_2 $$2MeSH$$aPeptide Fragments: blood
000274026 650_2 $$2MeSH$$aGlial Fibrillary Acidic Protein: blood
000274026 650_2 $$2MeSH$$aMass Spectrometry: methods
000274026 650_2 $$2MeSH$$aImmunoprecipitation: methods
000274026 650_2 $$2MeSH$$aNeurofilament Proteins: blood
000274026 650_2 $$2MeSH$$aAged, 80 and over
000274026 7001_ $$aKindermans, Jana$$b1
000274026 7001_ $$aVialaret, Jérôme$$b2
000274026 7001_ $$aAnderl-Straub, Sarah$$b3
000274026 7001_ $$aWerner, Leonie$$b4
000274026 7001_ $$aLehmann, Sylvain$$b5
000274026 7001_ $$aHirtz, Christophe$$b6
000274026 7001_ $$aOtto, Markus$$b7
000274026 7001_ $$0P:(DE-2719)9001560$$aOeckl, Patrick$$b8$$eLast author$$udzne
000274026 773__ $$0PERI:(DE-600)2506521-X$$a10.1186/s13195-024-01647-w$$gVol. 16, no. 1, p. 279$$n1$$p279$$tAlzheimer's research & therapy$$v16$$x1758-9193$$y2024
000274026 8564_ $$uhttps://pub.dzne.de/record/274026/files/DZNE-2025-00007.pdf$$yOpenAccess
000274026 8564_ $$uhttps://pub.dzne.de/record/274026/files/DZNE-2025-00007.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000274026 909CO $$ooai:pub.dzne.de:274026$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000274026 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001560$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000274026 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000274026 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-19
000274026 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-19
000274026 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000274026 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-19
000274026 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS RES THER : 2022$$d2023-08-19
000274026 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:09:21Z
000274026 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:09:21Z
000274026 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-19
000274026 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-19
000274026 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-19
000274026 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-19
000274026 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000274026 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-19
000274026 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-19
000274026 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bALZHEIMERS RES THER : 2022$$d2023-08-19
000274026 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-19
000274026 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-19
000274026 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-19
000274026 9201_ $$0I:(DE-2719)5000073$$kAG Öckl$$lTranslational Mass Spectrometry and Biomarker Research$$x0
000274026 980__ $$ajournal
000274026 980__ $$aVDB
000274026 980__ $$aUNRESTRICTED
000274026 980__ $$aI:(DE-2719)5000073
000274026 9801_ $$aFullTexts